Recently, Beijing JILUNTAI Pharmaceutical Co., Ltd. ("JILUNTAI"), a nuclear medicine innovation company invested and incubated by Baheal Pharma Group, achieved a significant R&D milestone. Its independently developed Class 1 innovative therapeutic radiopharmaceutical, ¹⁷⁷Lu-JLT003 injection (generic name: ¹⁷⁷Lu-AB-3PRGD2), has officially received an Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The drug is intended for the treatment of integrin αvβ3-positive malignant tumors.

This marks another major breakthrough for JILUNTAI on the integrin αvβ3 target, following the approval and launch in April this year of ⁹⁹ᵐTc-3PRGD2, the world's first integrin αvβ3-targeted diagnostic radiopharmaceutical independently developed by JILUNTAI. The IND approval extends JILUNTAI's innovative radiopharmaceutical R&D from diagnostics to therapeutics, gradually realizing the company's theragnostic strategy—the integration of diagnosis and therapy—against integrin αvβ3.

Prior to the formal IND approval, ¹⁷⁷Lu-AB-3PRGD2 injection had already shown promising clinical potential in investigator-initiated trials (IIT). The relevant research findings were presented as a rapid oral report at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, drawing significant international academic attention.

The study enrolled a total of 22 patients with advanced metastatic solid tumors, covering 13 cancer types including radioactive iodine-refractory thyroid cancer, breast cancer, lung cancer, cholangiocarcinoma, and renal cancer. Most were end-stage cancer patients with poor clinical prognosis and limited effective treatment options.

Results showed that the best overall disease control rate (DCR) for all patients during treatment was 90%. In subgroup analysis, among patients who received at least 3 cycles, 50% achieved stable disease (SD) and 20% achieved partial response (PR), yielding a DCR of 70% in that subgroup. Among those receiving at least 2 cycles, median progression-free survival (PFS) was 6.4 months and median overall survival (OS) was 18.5 months. Overall, ¹⁷⁷Lu-AB-3PRGD2 demonstrated favorable disease control and response across multiple end-stage metastatic solid tumors, with good tolerability.

Integrin αvβ3 is highly expressed in various solid tumors cells and tumor neovascular endothelial cells, while its expression in normal tissues is relatively low. This profile gives ¹⁷⁷Lu-AB-3PRGD2 broad-spectrum therapeutic potential across multiple solid tumors. Although the integrin αvβ3 target has been known for nearly 40 years and nearly 50 R&D pipelines have been pursued globally, the field long remained "research without products." That impasse was finally broken in April this year, when JILUNTAI's world-first integrin αvβ3-targeted diagnostic radiopharmaceutical, ⁹⁹ᵐTc-3PRGD2, received marketing approval—becoming China's first independently developed Class 1 innovative radiopharmaceutical. The IND approval of ¹⁷⁷Lu-AB-3PRGD2 signifies that JILUNTAI has achieved theragnostic integration on the same target, fully validating the company's sustained R&D strength in the radiopharmaceutical field.

JILUNTAI was founded by Professor Wang Fan of Peking University. The core R&D team, leveraging the "PKU Medicine-JILUNTAI Technology: Joint Laboratory for Nuclear Medicine Molecular Imaging," has established a radiopharmaceutical R&D platform covering the entire process of isotope labeling, targeted molecule screening and optimization, preclinical evaluation, and clinical translation. Its pipeline spans SPECT diagnostic agents, PET diagnostic agents, and targeted therapeutic agents, forming a complete innovation chain from basic research to clinical application.

The IND approval of ¹⁷⁷Lu-AB-3PRGD2 also marks another major milestone in Baheal's investment and incubation in the field of innovative drug. In 2022, Baheal made a strategic investment in JILUNTAI, formally entering the innovative nuclear medicine field. As an industrial investor, Baheal fully leverages its industrial resources to empower and synergize across R&D advancement, clinical translation, regulatory filing, and commercialization, helping JILUNTAI bridge the gaps from innovation to clinical application and market launch, and accelerating the translation of innovative achievements into practice.

Currently, Baheal has built a diversified portfolio across oncology, anti-organ fibrosis, cardiovascular diseases and etc., incubating multiple high-growth technology enterprises with core technological advantages. Looking forward, Baheal will continue to rely on its industrial ecosystem synergies to empower early-stage innovation, promote more domestically developed, high-clinical-value medical innovations to benefit patients, and truly optimize “Better science, better health.”

Reference

[1] ClinicalTrials.gov. Search Results for: αvβ3 [DB/OL]. [2026-08-31].

 https://clinicaltrials.gov/search?term=%CE%B1v%CE%B23&viewType=Card&rank=1&page=1&limit=10&sort=@relevance.